Molecular diagnostics firm Qiagen has received the US Food and Drug Administration (FDA) approval for its fourth-generation blood test developed to detect latent tuberculosis (TB) infection.
The new QuantiFERON-TB Gold Plus (QFT-Plus) test features CD8+ technology, which is expected to improve the insights into the immune system’s response to TB infection.
Initially launched last year, the test is currently available in more than 75 countries across the Middle East, Europe, Africa, Asia, and Latin America.
